[go: up one dir, main page]

NO20070323L - Organiske forbindelser - Google Patents

Organiske forbindelser

Info

Publication number
NO20070323L
NO20070323L NO20070323A NO20070323A NO20070323L NO 20070323 L NO20070323 L NO 20070323L NO 20070323 A NO20070323 A NO 20070323A NO 20070323 A NO20070323 A NO 20070323A NO 20070323 L NO20070323 L NO 20070323L
Authority
NO
Norway
Prior art keywords
organic compounds
drugs
formula
free
salt form
Prior art date
Application number
NO20070323A
Other languages
English (en)
Other versions
NO338319B1 (no
Inventor
Catherine Leblanc
Brian Cox
Kamlesh Bala
David Andrew Sandham
Katharine Louise Turner
Simon James Watson
Lyndon Nigel Brown
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20070323L publication Critical patent/NO20070323L/no
Publication of NO338319B1 publication Critical patent/NO338319B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det tilveiebringes ifølge oppfinnelsen forbindelser av formel (I) i fri eller saltform, hvori R1, R2, R3, R4, R5, R6, Q, W, X, m, n og p er som beskrevet i beskrivelsen, metode for å fremstille dem, og deres anvendelse som legemidler.
NO20070323A 2004-06-17 2007-01-17 Organiske forbindelser NO338319B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2005/006493 WO2005123731A2 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists

Publications (2)

Publication Number Publication Date
NO20070323L true NO20070323L (no) 2007-03-12
NO338319B1 NO338319B1 (no) 2016-08-08

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070323A NO338319B1 (no) 2004-06-17 2007-01-17 Organiske forbindelser

Country Status (28)

Country Link
US (5) US7666878B2 (no)
EP (1) EP1761529B3 (no)
JP (1) JP4886680B2 (no)
KR (1) KR101183330B1 (no)
AR (1) AR049443A1 (no)
AT (1) ATE378338T1 (no)
AU (1) AU2005254681B2 (no)
BR (1) BRPI0512060B8 (no)
CA (1) CA2569125C (no)
CY (1) CY1107851T1 (no)
DE (1) DE602005003365T3 (no)
DK (1) DK1761529T3 (no)
EC (1) ECSP067077A (no)
ES (1) ES2294717T7 (no)
HR (1) HRP20080022T4 (no)
IL (1) IL179604A (no)
MA (1) MA28666B1 (no)
MX (1) MXPA06014694A (no)
MY (1) MY144903A (no)
NO (1) NO338319B1 (no)
NZ (1) NZ551439A (no)
PE (1) PE20060301A1 (no)
PL (1) PL1761529T6 (no)
PT (1) PT1761529E (no)
RS (1) RS50552B (no)
RU (1) RU2379309C2 (no)
TW (1) TWI352702B (no)
WO (1) WO2005123731A2 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
KR101426093B1 (ko) 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
DK2051962T3 (da) 2006-08-07 2012-01-02 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-eddikesyrederivater
WO2009019504A1 (en) * 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
WO2009102462A1 (en) * 2008-02-15 2009-08-20 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
WO2010019909A1 (en) * 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Pyrrole inhibitors of s-nitrosoglutathione reductase
WO2010019903A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
AU2011231208B2 (en) 2010-03-22 2015-03-26 Idorsia Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
CA2818597A1 (en) * 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
SI2697223T1 (sl) 2011-04-14 2016-10-28 Actelion Pharmaceuticals Ltd. Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-A)indol-ocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6099051B2 (ja) 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するへテロ環誘導体
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
BR112016021471B1 (pt) 2014-03-17 2022-10-11 Idorsia Pharmaceuticals Ltd Compostos derivados de ácido acético azaindol, composição farmacêutica, e, uso de um composto
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
MY194204A (en) 2014-08-04 2022-11-21 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
WO2017015418A1 (en) 2015-07-23 2017-01-26 Merck Sharp & Dohme Corp. Genetic markers associated with response to crth2 receptor antagonists
TWI711616B (zh) 2015-09-15 2020-12-01 瑞士商愛杜西亞製藥有限公司 結晶型式
EP3353145B1 (en) 2015-09-23 2022-09-28 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
DK3356329T3 (da) 2015-09-29 2020-07-13 Novartis Ag Fremgangsmåde til fremstilling af 1-(4-methansulfonyl-2-trifluormethylbenzyl)-2-methyl-1H-pyrrolo[2,3-B]pyridin-3-yleddikesyre
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
EP3489235A4 (en) 2016-07-21 2020-01-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC COMPOUND AS CRTH2 INHIBITOR
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
AU2017406159B2 (en) 2017-03-30 2020-05-21 XWPharma Ltd. Bicyclic heteroaryl derivatives and preparation and uses thereof
JOP20190223A1 (ar) 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
IL305317B2 (en) 2017-06-30 2025-11-01 Univ California Compositions and methods for modulating hair growth
WO2019011336A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
CN111542519B (zh) 2018-01-19 2021-11-02 正大天晴药业集团股份有限公司 一种吲哚衍生物的晶型及其制备方法和用途
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CN113302190B (zh) 2019-01-15 2024-10-18 吉利德科学公司 Fxr(nr1h4)调节化合物
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
EP4077262B1 (en) 2019-12-20 2024-07-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4167971A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
EP4167966A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
JP7751638B2 (ja) 2020-10-05 2025-10-08 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2008502638A (ja) 2008-01-31
US20130267518A1 (en) 2013-10-10
NZ551439A (en) 2009-09-25
US20100204225A1 (en) 2010-08-12
ES2294717T7 (es) 2012-06-14
WO2005123731A2 (en) 2005-12-29
NO338319B1 (no) 2016-08-08
US8455645B2 (en) 2013-06-04
RU2379309C2 (ru) 2010-01-20
KR101183330B1 (ko) 2012-09-17
PL1761529T6 (pl) 2011-11-30
BRPI0512060B1 (pt) 2018-08-07
MY144903A (en) 2011-11-30
JP4886680B2 (ja) 2012-02-29
CA2569125C (en) 2013-01-08
MA28666B1 (fr) 2007-06-01
HRP20080022T3 (en) 2008-02-29
PE20060301A1 (es) 2006-05-18
US8791256B2 (en) 2014-07-29
US7666878B2 (en) 2010-02-23
DE602005003365T3 (de) 2012-08-30
HRP20080022T4 (hr) 2011-10-31
EP1761529B3 (en) 2011-06-15
BRPI0512060A (pt) 2008-02-06
EP1761529A2 (en) 2007-03-14
WO2005123731A3 (en) 2006-05-04
RU2007101277A (ru) 2008-07-27
PL1761529T3 (pl) 2008-04-30
KR20070032694A (ko) 2007-03-22
RS50552B (sr) 2010-05-07
DE602005003365D1 (de) 2011-01-05
AR049443A1 (es) 2006-08-02
MXPA06014694A (es) 2007-02-12
US20140309254A1 (en) 2014-10-16
US9169251B2 (en) 2015-10-27
AU2005254681A1 (en) 2005-12-29
DK1761529T3 (da) 2008-03-25
IL179604A (en) 2014-04-30
HK1103730A1 (en) 2007-12-28
ATE378338T1 (de) 2007-11-15
BRPI0512060B8 (pt) 2021-05-25
CA2569125A1 (en) 2005-12-29
TW200617009A (en) 2006-06-01
ECSP067077A (es) 2007-01-26
PT1761529E (pt) 2008-02-11
CY1107851T1 (el) 2013-06-19
EP1761529B1 (en) 2007-11-14
US8470848B2 (en) 2013-06-25
TWI352702B (en) 2011-11-21
IL179604A0 (en) 2007-05-15
ES2294717T3 (es) 2008-04-01
US20080114022A1 (en) 2008-05-15
AU2005254681B2 (en) 2009-01-29
US20100210610A1 (en) 2010-08-19
DE602005003365T2 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
NO20070323L (no) Organiske forbindelser
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE433447T1 (de) Pyrimiidinverbindungen
NO20081160L (no) Benzimidazoltiofen forbindelser
NO20090295L (no) Substituerte heteroarylderivater
NO20055135L (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
DE60328010D1 (de) Heterocyclische verbindungen
SE0202133D0 (sv) Novel compounds
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
NO20071593L (no) Pyrimidinderivater
NO20081217L (no) Nye benzotiazolonderivater
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
NO20076648L (no) Novel thiophene derivatives
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
NO20084583L (no) Makrosykliske kinase-inhibitorer
ATE477256T1 (de) Thienylverbindungen
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
TW200635921A (en) Organic compounds
SE0303541D0 (sv) New compounds
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees